Breast Cancer
Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
Published in Immunotherapy Weekly, May 20th, 2009
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it has completed enrollment in its Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. The planned 46 patients have been enrolled and are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label Phase II study is to assess the overall response rate to bavituximab and docetaxel. The company also announced that preliminary data from this trial has been accepted for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
"Completion of patient enrollment in this Phase II study in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2009-05-20)
More Articles from Immunotherapy Weekly
- Baylor College of Medicine
Process controlling T cell growth and production identified - NIH/National Institute of Environmental Health Sciences
New data analysis shows possible link between childhood obesity and allergies - Acorda Therapeutics, Inc.
Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing - Allergies
Research from M. Milovanovic and colleagues provide new insights into allergies - Biotechnology Business
Data on biotechnology business published by researchers at Amgen, Inc. - Cancer Vaccines
Studies from J. Grunewald and co-researchers update current data on cancer vaccines - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
